JP2011515478A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515478A5
JP2011515478A5 JP2011501946A JP2011501946A JP2011515478A5 JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5 JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5
Authority
JP
Japan
Prior art keywords
inhibitor
antibody
cdr
ser
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011501946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/037953 external-priority patent/WO2009142810A2/en
Publication of JP2011515478A publication Critical patent/JP2011515478A/ja
Publication of JP2011515478A5 publication Critical patent/JP2011515478A5/ja
Pending legal-status Critical Current

Links

JP2011501946A 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法 Pending JP2011515478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3919708P 2008-03-25 2008-03-25
US61/039,197 2008-03-25
PCT/US2009/037953 WO2009142810A2 (en) 2008-03-25 2009-03-23 Methods for treating or preventing colorectal cancer

Publications (2)

Publication Number Publication Date
JP2011515478A JP2011515478A (ja) 2011-05-19
JP2011515478A5 true JP2011515478A5 (cg-RX-API-DMAC7.html) 2013-03-14

Family

ID=41340744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501946A Pending JP2011515478A (ja) 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法

Country Status (8)

Country Link
US (1) US20110104256A1 (cg-RX-API-DMAC7.html)
EP (1) EP2259797A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011515478A (cg-RX-API-DMAC7.html)
CA (1) CA2718918A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009000721A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010010480A (cg-RX-API-DMAC7.html)
TW (1) TW200944233A (cg-RX-API-DMAC7.html)
WO (1) WO2009142810A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010056754A2 (en) 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
TWI460178B (zh) 2009-02-12 2014-11-11 Arqule Inc 組合性組成物及治療癌症之方法
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8580764B2 (en) * 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
WO2012030896A2 (en) 2010-09-01 2012-03-08 Arqule, Inc. Methods for treatment of non-small cell lung cancer
US20150141273A1 (en) * 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
NL2010276C2 (en) * 2013-02-08 2014-08-11 Stichting Vu Vumc Biomarkers.
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP6210640B2 (ja) * 2014-06-19 2017-10-11 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016309002B2 (en) 2015-08-20 2021-07-29 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
HK1257220A1 (zh) 2015-08-21 2019-10-18 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
WO2017136671A1 (en) * 2016-02-04 2017-08-10 Chattterjee Bandana Combination therapy for castration-resistant prostate cancer
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
EP3881847A4 (en) * 2018-11-14 2022-09-07 Kanazawa Medical University PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIFFUSE STOMACH CANCER
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084484B (en) * 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
AU2005286190A1 (en) * 2004-09-22 2006-03-30 Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Igfr抑制剤および抗癌剤の併用
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
EP2405270B1 (en) * 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US20100143340A1 (en) * 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.

Similar Documents

Publication Publication Date Title
JP2011515478A5 (cg-RX-API-DMAC7.html)
JP2011519868A5 (cg-RX-API-DMAC7.html)
JP2019503674A5 (cg-RX-API-DMAC7.html)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2012247438A5 (cg-RX-API-DMAC7.html)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
JP2014516964A5 (cg-RX-API-DMAC7.html)
US10544222B2 (en) PD1/CTLA4 binders
AU2016355569B2 (en) CTLA4 binders
CA3004748C (en) Pd1 and/or lag3 binders
WO2019199621A4 (en) Bi-functional molecules to degrade circulating proteins
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
JP2011515478A (ja) 結腸直腸がんを処置または予防するための方法
JP2005527222A5 (ja) 中和ヒト抗igfr抗体
JP2014516964A (ja) 治療用抗igf1r合剤
KR20170065466A (ko) 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체
JPWO2021055705A5 (cg-RX-API-DMAC7.html)
US9346846B1 (en) Anti-cancer compounds and methods for treating cancer
WO2025130666A1 (zh) 抗cd93抗体或其抗原结合片段及其应用
AU2018375719A1 (en) Compositions and methods for cancer therapy
NZ752184B2 (en) Antibody specifically binding to pd-1 and functional fragment thereof
NZ752184A (en) Antibody specifically binding to pd-1 and functional fragment thereof